Skip to Content

Novo Nordisk A/S Class B NOVOB

Rating as of

Morningstar’s Analysis

There is no Morningtar’s Analysis data available.

Company Profile

Business Description

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Contact
Novo Alle 1
Bagsvaerd, DK-2880, Denmark
T +45 44448888
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 46,574